3 results
Approved WMOCompleted
Primary Objective: To determine whether topical application of Calcitriol (Silkis) 3 µg/g, Diclofenac 10% or a combination of both can lead to a 40% histological reduction (*)/increase (*) of expression of the following antibodies: Ki67 (*), BCL2…
Approved WMORecruiting
To investigate the mechanism of fatigue and inflammation in IBD using clinical biomarkers, transcriptomic and epigenetic sequencing, and an innovative health patch.
Approved WMORecruiting
To address whether the individualized fludarabine conditioning reduces the incidence of severe viral infections at day 100 within the context of an αβTCR / CD19 depleted transplantation regimen.